Welcome to our dedicated page for Mira Pharma SEC filings (Ticker: MIRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mira Pharmaceuticals’ SEC paperwork can feel like a pharmacology textbook—dense risk factors on early-stage trials, frequent capital raises and complex share structures. If you’ve ever Googled “Mira Pharmaceuticals SEC filings explained simply” or asked, “where do I track Mira Pharmaceuticals insider trading Form 4 transactions?” you know how time-consuming the search can be. Stock Titan’s AI-powered summaries surface the essential numbers, milestones and red-flag disclosures in seconds, replacing hours of page-turning.
Whether you’re after the latest Mira Pharmaceuticals quarterly earnings report 10-Q filing to monitor R&D burn, want Mira Pharmaceuticals 8-K material events explained right after an FDA meeting, or need Mira Pharmaceuticals executive stock transactions Form 4 delivered in real time, our platform has you covered. Every document arrives straight from EDGAR and is paired with concise natural-language explanations, ratio tables and auto-generated comparisons. Understanding Mira Pharmaceuticals SEC documents with AI means spotting dilution clauses, patent expirations and cash-runway projections without wading through footnotes.
Investors use these insights to price upcoming IND submissions, compare quarter-over-quarter spending and benchmark peer pipelines. Want a Mira Pharmaceuticals annual report 10-K simplified? Our AI highlights trial timelines, intellectual-property positions and going-concern statements. Need a Mira Pharmaceuticals proxy statement executive compensation breakdown before the next vote? It’s already summarized, along with Mira Pharmaceuticals earnings report filing analysis and Mira Pharmaceuticals Form 4 insider transactions real-time alerts. Stop scrolling and start focusing on the decisions that matter.
Denil Shekhat, a director of MIRA PHARMACEUTICALS, INC. (MIRA), reported on Form 4 that on 10/01/2025 she acquired 22,378 restricted shares of the issuer's common stock at a price of $1.35 per share. The filing shows the shares were issued as compensation in connection with the issuer's acquisition of SKNY Pharmaceuticals, Inc. Following the transaction the reporting person beneficially owns 22,378 shares in a direct ownership form. The Form 4 was signed on 10/03/2025 and was filed by one reporting person.
Erez Aminov, who is listed as both Chief Executive Officer and a Director of Mira Pharmaceuticals, Inc. (MIRA), reported an acquisition of 2,685,456 restricted shares of the issuer's common stock on 10/01/2025. The filing shows 3,530,156 shares beneficially owned following the transaction, held in a direct ownership form. The restricted shares were issued as compensation to Mira in connection with the company’s acquisition of SKNY Pharmaceuticals, Inc., per the explanatory note. The Form 4 is signed by Mr. Aminov on 10/03/2025.
MIRA Pharmaceuticals filed a Form 3 reporting initial beneficial ownership following a transaction dated 09/29/2025 involving Telomir Pharmaceuticals, Inc. (TELO). The filing shows the reporting person is identified as a director and discloses ownership of 3,521,127 shares of the issuer's common stock, no par value. The shares were acquired in connection with the reporting person’s acquisition of SKNY Pharmaceuticals, Inc. The Form 3 is signed by Erez Aminov, CEO on 10/03/2025.
MIRA Pharmaceuticals' CEO and director received repriced, fully vested stock options totaling 300,000 shares. The company’s board lowered the exercise price on two existing option grants—from $5.00 and $6.50—to $1.38, while leaving all other terms unchanged. Each repriced grant covers 150,000 options and remains exercisable into common stock with specified expiration dates in 2033. The disclosure shows the holdings are held directly by the reporting person and that the repricing was approved by the board, which materially changes the economic value of the previously issued awards.
Erez Aminov, Chief Executive Officer and Director of MIRA Pharmaceuticals, Inc. (MIRA), reported on Form 4 that 62,500 restricted stock units (RSUs) vested and were issued to him on 08/29/2025 at a reported price of $1.37 per share. The RSUs were granted under the company's 2022 Omnibus Incentive Plan and vesting followed achievement of specified milestones under the Reporting Person's Executive Incentive Compensation Plan.
Following the issuance, Aminov beneficially owned 844,700 shares according to the filing. The Form 4 was signed on 09/03/2025.
FAQ
What is the current stock price of Mira Pharma (MIRA)?
What is the market cap of Mira Pharma (MIRA)?
